Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- MEDICAL DEVICE NEWS IN BRIEF
August 8, 2005
- List of Issues to Be Discussed Proposed by Korosho
August 8, 2005
- SEMINAR
August 8, 2005
- Proposed Issues to Be Discussed for Reform of the NHI Pricing System
August 8, 2005
- Tablets Associated with Better Compliance: Cancer Pain Survey
August 8, 2005
- Import of Banyu's Propecia Recommended for Approval
August 8, 2005
- REGULATORY NEWS IN BRIEF
August 8, 2005
- Tsumura Announces New 3-Year Management Plan
August 1, 2005
- Nichi-iko to Do More Business through Wholesalers, Sell More to DPC Hospitals
August 1, 2005
- Parexel Working to Expand Business in Japan
August 1, 2005
- Asahi Kasai Publishes FY2004 Report on Intellectual Properties
August 1, 2005
- BUSINESS NEWS IN BRIEF
August 1, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 1, 2005
- Kyowa Hakko to Speed Up POC Studies: Dr Matsuda
August 1, 2005
- NEW PRODUCTS
August 1, 2005
- Sankyo Resumes Development of CR-917 for Treatment of Diabetes
August 1, 2005
- MEDICAL DEVICE NEWS IN BRIEF
August 1, 2005
- R&D NEWS IN BRIEF
August 1, 2005
- SURVEY 2 articles
August 1, 2005
- OPINION
August 1, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…